Solasia Pharma K.K (9SO F) stock market data APIs
€0.2277
0(0%)
as of February 14, 2025
Solasia Pharma K.K Financial Data Overview
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liduid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
Prev. Close
0.2257
Open
0.2277
High
0.2277
Low
0.2257
52 wk Range
0.13-0.382
Market Cap
54 229 K
Shares Outstanding
218 M
Revenue
316 M
Beta
1.327
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Solasia Pharma K.K data using free add-ons & libraries
Get Solasia Pharma K.K Fundamental Data
Solasia Pharma K.K Fundamental data includes:
- Net Revenue: 316 M
- EBITDA: -1 912 999 936
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Solasia Pharma K.K News
New
Solasia Announces Launch of Darvias® in Japan
TOKYO, August 22, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoa...
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
TOKYO, June 20, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoarse...
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO, October 26, 2021--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") and Nippon Kayaku Co., Ltd. (TOKYO: 4272...
Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan
NDA filed in Japan ahead of anywhere else in the world New anti-cancer drug with a novel mechanism of action Darinaparsin is designated Orphan Drug in the US and EU as a treatment of peripheral T-cell...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
